VetCell is celebrating a win at Cheltenham, after 'Knowhere' won the Cotswold Chase following pioneering stem cell treatment for a serious tendon injury.
Knowhere had had a good start to his racing career as a four-year-old, winning his first two races as a novice hurdler. But after his second race in 2004 he suffered injuries to both forelimb superficial digital flexor tendons. The left fore showed low grade tendonitis while the right fore had a significant percentage of fibre rupture. As a promising racing prospect, Knowhere’s connections wanted to give him the best possible chance of recovering from his injury so they opted for stem cell therapy. He was treated by Tim Beauregard MRCVS of Summerhill Farm in Gloucestershire.
Bone marrow samples were collected from Knowhere’s sternum and were processed in VetCell's laboratory over a five week period to generate millions of stem cells. Knowhere was sedated, the tendon area was anaesthetised and the leg was then surgically clipped and disinfected. Stem cells, which had been suspended in serum obtained from the original bone marrow sample, were then injected using ultrasound guidance, into the core of the damaged area of the tendon fibres.
For the first week after the implantation Knowhere was kept in his stable to allow the cells to adapt to their new environment. Each day after this he was given walking exercise in order to stimulate the activity of the stem cells, encouraging them to differentiate into tendon cells and form into strong tendon fibres. The amount of exercise was incrementally increased, building up over a three-month period from five minutes each day to 45 minutes twice a day.
By the autumn of 2005 both of Knowhere’s tendons had healed very well and showed good fibre pattern on ultrasonography. He was re-introduced to the racetrack the following year and of the 15 or so races he has been in since, he has finished in the frame on eight occasions and has amassed some £175,000 in winnings.
Vet Tim Beauregard said: “Knowhere’s successful return to the track has been exciting and immensely satisfying to follow and he showed particularly brilliant form in the Cotswold Chase. It remains to be seen whether he will be heading for the Ryanair Chase, the Gold Cup or the Grand National but all involved will be hoping for the best.”
For more information please contact VetCell on +44 207 691 2062 or 866 764 0340, email: info@vetcell.com or visit the website at http://www.vetcell.com/
Dunlops has changed its name to Henry Schein Animal Health.
David Hinton, Managing Director said: "As we change our name to Henry Schein Animal Health, we also reaffirm our company's strong commitment to offer a comprehensive array of products and services to help animal health practitioners in the United Kingdom operate more efficient and successful practices, and provide the best quality patient care.
"We have a new name, but we have the same strong team, the same values, and the same dedication to providing excellent service to our customers."
Henry Schein Animal Health’s expanded offerings include VetLink and Thrive. VetLink is a new e-commerce web site system that enables veterinary surgeons to access the growing internet sector, allowing you to sell anything from pet prescriptions to accessories online, to be delivered to your customers’ homes by Henry Schein Animal Health. Thrive is a new veterinary business analysis service that integrates with practice management software to use a Key Performance Indicator based approach that provides insight into a your practice and identifies areas where you can enhance your business.
The initiative comes after BEVA's new nurse committee ran a survey which found a poor understanding within the profession and amongst clients of what equine nurses can do.
Nurses said they believed they could be given more responsibility and do more within their roles and that there was a lack of opportunity for progression.
BEVA President David Rendle, who is championing this initiative, said: “RVNs are a significant an asset to any equine practice.
“They have invested a lot of time and effort to become highly skilled but in some instances their significant attributes are not being utilised to the full.
“Allowing RVNs to perform the clinical tasks that they are qualified to carry out under Schedule 3 of the Veterinary Surgeons Act 1966, will provide better job fulfilment and career development as well as free up veterinary surgeons to carry out other tasks, all increasing the efficiency of the veterinary team.
“I feel, and the RVN survey results would seem to confirm, that veterinary surgeons and practice managers do not appreciate how much veterinary nurses are allowed to do in equine practice.
"We all know veterinary nurses have the ability; look at what they do in small animal and human nursing, but we have felt unnecessarily constrained by Schedule 3 of the Veterinary Surgeons Act 1966 and the associated RCVS guidelines.
"If you actually look at Schedule 3 it is clear that we can and should be letting our qualified equine nurses do far more.
“There are so many things in equine practice that nurses do better than vets.
"In addition to performing clinical tasks they can add wider value; they are generally (or are perceived by clients to be!) more patient, empathetic and caring so we should utilise these skills and get nurses to take on some of the roles that take more time and require longer client interactions – discussing parasite control programmes, running weight loss clinics, reviewing healthcare plans, making follow-up phone calls and visits to name just a few.
"Nurses can take a lot of pressure off vets and can add a significant revenue stream for the practice.”
On the 9th February, the BEVA will be hosting an online discussion forum for all members of the practice team to discuss the role of nurses and how their skills, experience and knowledge can be better-used.
It's free for BEVA members: https://www.beva.org.uk/Home/Events/BEVA-Events/Event-Details.aspx?eventDateId=1716
Marie Rippingale Chair of the BEVA Nurse Committee said: “Last year’s recruitment and retention survey revealed that 50% of nurse respondents were earning less than £25,000 per annum and 48% of nurses said they were likely to look for a new job in the next two years.
"When asked their top reasons for leaving, salary was the biggest reason, and common themes on what would help the retention of nurses included salary, work-life balance and career progression.
“The review of Schedule 3 is important so we can encourage delegation of tasks to RVNs.
"This will allow RVNs to demonstrate their value and worth, earning money for the practice and achieving job satisfaction at the same time. This will contribute positively towards the current retention crisis.”
To find out more about what equine veterinary nurses can do in practice visit https://www.beva.org.uk/nurses
Photo: Liphook Equine Hospital.
The event is held every four years and hosted alternately by BEVA and the American Association of Equine Practitioners (AAEP).
It offers the opportunity for equine vets to absorb and digest the latest knowledge, clinical practice and scientific advances in the treatment and prevention of colic, from the world’s leading international equine gastroenterology experts.
Held over 2.5 days, the symposium comprises numerous 12-minute oral presentations on a range of topics including surgical techniques, treatment, parasitology, gastric ulceration, endotoxemia, pharmacology of intestinal motility, colic complications, epidemiology, physiology of digestion, the intestinal microbiome and metabolomics.
Each session will be followed by three minutes for questions and discussion.
Poster sessions on the first two days will cover ground beyond the oral presentations and delegates will be able to review and discuss the work with presenters.
There will also be opportunities to network with other equine vets, researchers and professionals.
Clinicians and scientists have until 1 February 2024 to submit abstracts of recent work that they wish to present at this meeting.
The scientific committee will consider abstracts on all aspects of equine gastroenterology, including basic science research and reports of clinical cases or novel approaches to treatment.
The abstract submission form is here: https://form.jotform.com/230473925626359
Tickets cost £475 (with a concessionary rate of £235 for post graduate students and interns) and includes a drinks reception on both 10th & 11th, an evening buffet and Ceilidh on 11th and lunch on 11th & 12th.
Further information and booking details can be found here: https://www.beva.org.uk/Education/CPD/Event-Details/eventDateId/1740
Congratulations to Merial for a creative initiative to celebrate the 25th birthday of Eqvalan®.
The company made a much needed donation towards the upkeep of the Pewsey White Horse in return for being able to use it as part of Eqvalan's birthday celebration publicity programme for 2008.
The money will be used to restore the protective fencing around the ancient landmark, near Marlborough in Wiltshire.
Merial's Claire Parry- Baggott explains: "There are a number of white horse sites across the UK, many of which are extremely popular visitor destinations. To keep these sites open to the public requires year-round maintenance, often from a small army of volunteers.
"Horse owners have been using Eqvalan to help protect their trusty companions for 25 years, and this initiative will help provide protection of a different kind!
"The idea sprang from the current Eqvalan advertising campaign which celebrates 25 years of worming protection. The result is a fantastic 100 feet replica of our Eqvalan birthday horse, and brand new fencing for the Pewsey White Horse!
"We were delighted to help the Pewsey Council raise funds to preserve the site and hopefully this money will enable the horse to be enjoyed by many for years to come," concludes Claire.
A research project funded by The Horse Trust has made important discoveries about how two peptides regulate the inflammatory response in horses. This knowledge could help with the development of improved anti-inflammatory drugs, which are used to treat a wide range of conditions in horses.
The research project was led by Professor Fiona Cunningham at the Royal Veterinary College in Hertfordshire and Dr Karen Rickards at the Donkey Sanctuary in Sidmouth, assisted by Dr Andrew Brooks at the RVC, and by Dr Kirstie Pickles, now at the Royal (Dick) School of Veterinary Studies in Edinburgh.
Inflammation is associated with a wide range of equine diseases, including recurrent airway obstruction, laminitis and sweet itch. Anti-inflammatory drugs, such as glucocorticosteroids, mainly work by blocking the formation and/or actions of compounds produced in the horse's body that cause inflammatory responses. However, these drugs are not always effective and can have unwanted side effects.
This research, funded by The Horse Trust, aimed to find out more about two naturally-occurring peptides - chains of amino acids that are shorter than proteins - known as annexin-1 and CXCL8. Both have been shown to affect the inflammatory response but little research has been done on their effects in horses. In the long term, knowing more about these compounds could help in the development of new anti-inflammatory drugs with fewer side effects.
During inflammation, neutrophils (a type of white blood cell) stick to the cells lining blood vessels and migrate into inflamed tissue, where they ingest and break down harmful agents. Using techniques that mimic these events, CXCL8 was found to cause adherence and migration of horse neutrophils. However, when it was used in combination with another pro-inflammatory substance, neutrophil migration and adherence were markedly decreased. This suggests that attempts to reduce inflammation by blocking the actions of CXCL8 might not be as beneficial as had been thought.
At the start of the project, the researchers had no information about horse annexin-1, other than its gene sequence, so their first step was to develop a method to detect the peptide in white blood cells. They established that it was present and, as horse annexin-1 has not yet been synthesised, they used a synthetic peptide derived from annexin-1, Ac2-26, to look at the effects on horse neutrophils.
They found that Ac2-26 decreased neutrophil adherence and migration in response to other pro-inflammatory compounds, although at high concentrations the peptide itself caused some cell activation, thereby increasing inflammation. They also found that dexamethasone (a glucocorticosteroid) increased the levels of annexin-1 in cells, indicating that, as in humans, this class of drugs is likely to act in part through the formation of annexin-1.
These findings suggest that the use of compounds which mimic the actions of annexin-1 may have limitations as anti-inflammatory drugs. As glucocorticosteroids partly work by forming annexin-1, further research is needed in order to find out how annexin-1 will act in the horse's body and establish how its formation contributes to the beneficial effects of these drugs.
Professor Cunningham said: "This Horse Trust-funded research has resulted in some very interesting findings about how inflammatory cells are regulated in horses. The receptors that annexin-1 and CXCL8 act upon could be targets for new equine inflammatory drugs, but more research is needed first to fully understand their actions and how they produce these effects."
The team's research has been accepted for publication by the journal Veterinary Immunology & Immunopathology.
The review, announced earlier this year, was recommended to RCVS Council by its Standards Committee following its exploration of the implications of new technologies for both animal health and welfare and veterinary regulation.
The main areas under consideration include the provision of 24-hour emergency cover and the interpretation and application of an animal being under the care of a veterinary surgeon.
The initial stages of this review had been drafted for Standards Committee to consider at its meeting on 9 September, where the outline timetable was also discussed.
Standards Committee Chair Melissa Donald, said: "This is set to become one of our most fundamental reviews of RCVS guidance in recent years.
"Considering the complexity of the issues in question, and their importance to animal owners and the professions alike, it is vital that we allow ourselves enough time to ensure this review is as thorough and comprehensive as possible.
"We have a clear responsibility to seek, understand and, where we can, accommodate the opinions and experiences of as many different people from within and around the professions and the public as possible. I would urge my fellow vets and vet nurses to please find some time to consider these issues very carefully over the coming weeks and months, and to send us their views."
The review will comprise several stages and is expected to take around 12 months to complete. The outline timetable, which may be subject to change, is as follows:
October 2019 – January 2020: six-week Call for Evidence, followed by independent qualitative analysis of all evidence received
February – March: Select Committee-style meetings and independent qualitative analysis of additional evidence gathered [NB this stage is subject to Standards Committee requirements, depending on the evidence gathered.]
April – June: Consider all evidence and draft any new policy
July – August: six-week public consultation on draft policy
September – October: independent review of consultation responses, and production of any proposals for change
November 2020: Finalise any proposals for change and publish any new guidance
To support and promote the various stages of the review the College is also planning a programme of stakeholder engagement, and will also provide regular updates on progress to both Council and the wider profession.
Members of the professions and the public will be able to follow the progress of the review via the RCVS website at: www.rcvs.org.uk/undercare
The apple-flavoured, gastro-resistant granules can be mixed with dry feed to make administration easier for owners.
Animalcare says that up to 37% of leisure horses and 93% of race horses are reported to be affected by gastric ulcers1, for which the most prescribed treatment is omeprazole.
Equizol’s granule formulation has been developed to support owners who find syringe administration difficult or wasteful. It is presented in packs of 28 sachets, each containing sufficient omeprazole to treat 200 kg body weight. Owners mix the appropriate number of sachets into a small amount of the horse’s feed.
Animalcare Product Manager James Beaumont said: “Offering innovative product solutions which better meet our customer’s needs is our goal and Equizol is a perfect example. Our established equine healthcare range includes products for pain management, infusion therapy and microchips. Now, with the launch of Equizol, we are offering an innovative, easy-to-use and cost-effective solution to the common problem of gastric ulcers, based on tried and trusted omeprazole. We are delighted to add it to our range.”
Reference
The study, titled ‘Physics of animal health: On the mechanobiology of hoof growth and form’, represents the fruit of a collaboration between researchers in equine medicine, maths, physics and stem cell biology. It was conducted by the School of Veterinary Medicine and Science at University of Nottingham in collaboration with the Waltham Centre for Pet Nutrition and the Royal Veterinary College.
Lead author Dr Cyril Rauch said: "With new scientific inputs from physics, mathematics and biology, this study provides an entirely new paradigm regarding hard growing tissues such as the horse hoof, which can be applied across cattle, sheep and other species, to unify a set of apparently disparate conditions and clarify the roles of physics and/or biology."
Using hooves from horses euthanased for non-research purposes, the study revealed how it is possible for the hoof growth rate to be greater than the potential proliferation rate of epithelial cells. It also explained how the synthesis of the hoof capsule starts from the coronet and that the soft papillae undergo gradual transition through three interpapillary regions into hard keratinised tissue.
Mathematics, physics and cell biology were then used in the study to explain and describe how the dorsal hoof wall can grow in a curved manner rather than the usual straight manner as a result of faster growth from the coronary band at the quarters compared to the toe region.
Evaluation of the feet from live underweight and obese subjects (assessed using Body Condition Scoring) allowed the influence of body weight on the balances of the stresses affecting hoof growth to be evaluated. The results suggest that being proportionally heavier may promote straighter hoof growth and that being too lean may precipitate poor hoof growth and the development of a hoof with a dorsal curved shape.
The study also showed that a high concentration of insulin stimulated equine progenitor keratinocytes (the outermost layer of cells on the hoof wall) to grow in culture. If this also happens chronically within the live animal, it is possible that it could affect the growth stresses within the hoof and so promote a dorsal curved hoof shape.
Co-author Nicola Menzies-Gow said: "These results taken together can explain how the hoof grows and how it is possible for it to develop a dorsal curvature. However, it should be acknowledged that this does not take into account the genetic or metabolic influences on hoof growth nor the role of hoof trimming and shoeing in maintaining a mechanically healthy hoof. It is appreciated that the underlying biology of hoof growth remains an essential factor for hoof pathologies."
Dr Cyril Rauch continued: “Given that the hoof is a weight bearing element it is essential to untangle the biology from the physics in this system; only then can meaningful biological and/or physical causes be prescribed for particular hoof shape. Removing the cause(s) when physically or biologically possible is essential to resolve hoof conditions."
The British Equine Veterinary Association (BEVA) has clarified regulations on equine dental procedures following a survey which showed confusion, even amongst vets, over who is allowed to do what in a horse's mouth.
In the survey of BEVA members, more than half were unaware of the dentistry techniques that equine dental technicians (EDTs) are permitted to perform and the levels of veterinary supervision required.
In response, the association has put together a new information leaflet which explains the regulations surrounding equine dental care and describes where recommended practice differs from the letter of the law.
All diagnostic and treatment procedures in the horse's mouth are Acts of Veterinary Surgery under the Veterinary Surgeons Act 1966. The only exception is the manual removal of small dental overgrowths and sharp enamel points with hand instruments.
However it is acknowledged that there are a limited number of procedures that, despite being considered Acts of Veterinary Surgery, may be delegated safely to suitably qualified EDTs without compromising the horse's welfare and safety. In 2009 the RCVS, with assistance from BEVA, BVDA and BAEDT, listed these processes and categorised all dental procedures into three groups:
Despite there being no legal basis supporting non-vets performing Category 2 procedures, the RCVS has stated that there would be no public interest in prosecuting vets who collaborate with suitably qualified EDTs to perform non-invasive (Categories 1 and 2) procedures.
BEVA recommends that, for their own protection, all vets who deal with horses:
Vicki Nicholls, equine vet at Wright and Morten in Cheshire, chair of BEVA council's Paraprofessional Committee and member of the British Association of Equine Dental Technicians (BAEDT) said: "The lack of awareness is alarming and clearly emphasises the need to make vets and equine dental technicians fully conscious of current regulations regarding equine dentistry. Non-adherence to the regulations is a serious matter and could lead to prosecution of the veterinary surgeon, EDT and/or owner."
The number of vets taking the BEVA/BVDA exam in equine dentistry has increased in recent years with about 15% of those who have passed the exam being vets. BEVA says this is indicative of the growing awareness, amongst owners and vets, of the importance of dental health. It also reflects a desire to develop and demonstrate both practical skills and a theoretical understanding of equine dental care to augment the vet's broader medical knowledge. Expertise in equine dental care has, for many veterinary practices, become a valuable asset.
Copies of the dental regulations information leaflet can be downloaded from the BEVA website at www.beva.org.uk. BEVA also runs regular dentistry CPD courses, details of which can be found on the website.
Image source: Rachel C from Scotland
The Horse Trust is funding a three-year project to develop a genetic diagnostic test for Fell Pony Syndrome (FPS) and thus enable control and possible elimination of the disease.
The work will be undertaken at the Animal Health Trust, Newmarket, and the University of Liverpool Veterinary School.
The Fell pony, an ancient British pony breed categorised as "at risk" by the Rare Breeds Survival Trust, has over the past decade or so been subject to a severe immune deficiency known as Fell Pony Syndrome (FPS), which results in the death of some of the newborn foals.
Foals affected with FPS appear normal at birth but within a few weeks begin to lose condition and suffer diarrhoea, coughing and weight loss. Severe anaemia and immune dysfunction follows, leading to wasting and finally death. The disease is always fatal.
As a large percentage of these ponies live and breed on the fell, the prevalence of FPS is unclear. Despite an improvement in foal registration numbers in recent years, Fell Pony Syndrome remains of concern to breeders.
Studbook analysis and knowledge of affected foals strongly suggests that this is an inherited disease caused by an autosomal recessive genetic mutation. A DNA based test for this mutation would enable carriers of FPS to be identified and the conception of affected foals prevented.
As well as identifying carriers in the Fell pony population, the project will be used to identify any carriers in other breeds which have been involved in the extensive outbreeding of Fell ponies over the years.
"The success of this project will prevent the suffering of newborn Fell pony foals affected with FPS," says project leader Dr June Swinburne, senior post- doctoral equine molecular geneticist at the Animal Health Trust Centre for Preventive Medicine. "Foals affected by the condition inherit an incurable genetic defect which results in severe wasting and a profound anaemia together with multiple infections. Veterinary intervention is in vain and once the condition is diagnosed foals are often euthanased. The gradual but relentless decline in these foals leaves both veterinary surgeons and breeders powerless.
"Breeders are supportive of our attempt to develop a diagnostic test which will help to prevent carrier-carrier matings, one in four of which results in an affected foal."
The Horse Trust's Chief Executive and resident veterinary surgeon Paul Jepson said: "This is an exciting and achievable project with significant benefits for equine health and welfare, as it will lead to the prevention and elimination of a fatal disease."
Dechra Pharmaceuticals PLC has announced that it has acquired the entire issued share capital of Genitrix Limited ("Genitrix") from its owner managers for an initial cash consideration of £5.4 million, with a further £0.8 million being payable upon achievement of specific milestones.
Dechra says the acquisition of Genitrix is consistent with its strategy to grow its international veterinary pharmaceutical business. In the year ended 31 March 2010, Genitrix achieved revenues of £2.4 million.
Ian Page, Chief Executive of Dechra, said: "Genitrix range of equine and companion animal products enhances and complements our UK product portfolio. Furthermore the recently approved canine epilepsy product, Libromide, provides future growth opportunities through potential mutual recognition in Europe. The acquisition is expected to be earnings enhancing in the first full year following ownership."
Fort Dodge has announced that a challenge study has demonstrated the ability of Duvaxyn® IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Sydney/07 (H3N8) two weeks after a two dose primary course. This strain was responsible for the financially devastating equine influenza outbreak in Australia in August 2007.
Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. According to Fort Dodge, experts at a recent WHO meeting on human vaccines expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine*.
The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Sydney/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
Helen Barnes, EMEA Equine Business Manager for Fort Dodge, said: "The results of this challenge study provide reassurance for owners that horses vaccinated with Duvaxyn will be protected against circulating strains of equine influenza, including the Sydney strain which proved so damaging.
"As the benefits offered by whole virus technology are increasingly recognised, the popularity of vaccines based on this technology is re-emerging, particularly to combat a potential pandemic.
"The entire Duvaxyn range of equine vaccines, including the recently licensed Duvaxyn WNV for West Nile Virus, are based on the whole virus approach as we believe it offers a broad and consistent level of protection."
Blue Cross has announced the results from its National Equine Health Survey (NEHS) which show that lameness is three times more likely to be caused by conditions such as osteoarthritis in the limb rather than problems in the foot.
Blue Cross runs NEHS in May each year, in partnership with the British Equine Veterinary Association (BEVA). It is sponsored by SPILLERS and Zoetis and supported by the UK’s leading equestrian organisations and charities. This year saw a 35% increase in participation compared to 2014, with survey records returned for almost 15,000 horses, ponies, donkeys and mules.
The charity says that whilst of course the horse’s foot is fundamental to soundness and performance, NEHS results have shown consistently that limb lameness, as opposed to foot lameness, is in fact the biggest syndrome affecting horses.
In the latest survey, conducted in May, a total of 18% were recorded as lame. 13.5% of these were recorded as suffering with lameness such as osteoarthritis, also known as degenerative joint disease (13.9% in 2014 and 14.8% in 2013).
Meanwhile foot lameness was recorded in 4.5% of returns, a similar figure to previous years.
Josh Slater from the Royal Veterinary College, who is member of BEVA’s Health & Medicines Committee and analysed the NEHS data, said: “NEHS is now producing important evidence that is replacing subjective opinion. While the lameness figures were initially surprising, given that the foot has been generally regarded as the main problem area, the fact that these figures have remained consistent over the past three years gives constructive credibility to the data. Our findings will help owner vigilance with day-to-day healthcare as well as help prioritise on areas for future veterinary education and research.”
The six most notable disease syndromes identified in the 2015 National Equine Health Survey were:
23.2% of horses were reported as being overweight with a Body Condition Score of 3.5-5, continuing the upward trend seen in previous years (16.9% in 2014 and 7.8% in 2013). Next year’s survey will explore links between obesity and the possible associated rise of obesity-related diseases such as equine metabolic syndrome (which was reported in 2.4% of 2015 returns) and laminitis.
The survey also enables participants to report on any health problems not covered in the survey questions, giving them a chance to shape future survey subjects.
Gemma Taylor, Education Officer at Blue Cross explains: “This year 11% of our free text answers mentioned gastric ulcers giving a valuable insight into the prevalence gastric ulcer syndrome in the principally leisure horse NEHS population. As a result we will be adding new questions to the 2016 survey to help us find out more.”
The 2015 NEHS survey results are now available from http://www.bluecross.org.uk/nehs2015results. To register for next year’s survey, visit www.bluecross.org.uk/nehs
The ioLight microscope fits in a jacket pocket and the company says it is both simple to use and robust. It unfolds to record and share 5MP still images and real time HD video at a magnification of x200 on an iPad Air. The resolution is 1 micron or 1/1,000 mm, powerful enough to see the structure of plant and animal cells.
The microscope uses standard microscope slides and has adjustable top and bottom illumination for use on both biological and opaque samples.
Iolight says it is particularly good for live samples which deteriorate on the journey back to the lab, and it works anywhere, even without a WiFi or mobile phone network.
Andrew Monk, who founded ioLight with business partner Richard Williams, said: "It takes just a couple of minutes to get a great image on the microscope, anywhere from a river bank to a factory floor. This makes microscopy simpler for everyone, from experienced professionals to student scientists."
The ioLight microscope can be ordered now from www.iolight.co.uk, priced at £840 including VAT.
The new resources include the Equine Veterinary Journal’s (EVJ) publication of BEVA’s Primary Clinical Care Guidelines on wound management in horses together with BEVA’s first ever digital CPD course: 'How to Heal Wounds – a masterclass for vets and vet nurses'.
The new guidelines cover three key areas: wound lavage and topical treatments; wound debridement and closure and therapeutics for wound healing.
Sarah Freeman, who led the project, said: "These guidelines are aimed at the vast majority of our membership who are primary care practitioners. Topics covered are voted for by BEVA’s panel of specialists and represent a benchmark in time against the strength and weakness of evidence that support it."
The wound management guidelines follow BEVA’s recommendations on the safe use of analgesia in horses, which were published earlier this year.
BEVA’s new online course: 'How to Heal Wounds' is aimed at mixed and equine practitioners and veterinary nurses who encounter wounds in horses.
Led by Dr Patrick Pollock BVMS, PhD, CertES(Soft Tissue), DipECVS, FHEA, FRCVS along with teaching from leading names including Professor Derek Knottenbelt OBE, BVM&S, DVM&S, DipECEIM, MRCVS, Dr Dylan Gorvy BSc, BVSc, PhD, CertES(Soft Tissue), DipECVS, and Ms Georgie Hollis BSc it will provide key concepts of wound physiology and introduce new treatment ideas and modalities designed to optimise wound healing.
Tim Mair Chair from BEVA’s Education Committee said: “This course is an absolute masterclass for vets and vet nurses. It contains 12 on-demand recorded lectures, together with the opportunity to attend up to three live discussions with the speakers. The final live discussion will provide the opportunity for the delegates to trouble shoot with our speakers after being able to go and practice the skills and knowledge learnt on the course.”
The course will be available from August 2020. It will cost £65 for BEVA members (£130 for non-members), which includes access to course resources for up to a year – meaning if they can’t attend a live discussion, they can watch it later.
Photo: Dr G Quinn.
The 2020 OV Conference will offer up to 25 hours of CPD with lectures, workshops and Q&A sessions from world-class speakers in streams covering small animals, farm animals and equines. There will also be exclusive offers from industry sponsors and online networking opportunities.
The OV Conference provides an opportunity for OVs to discuss current topics of interest and recent developments in their work. Themes this year will include notifiable diseases, biosecurity and disease control, and export certification.
In addition to the live lectures, delegates will be able to view recordings of all the sessions on-demand for three months following the conference. The CPD on offer counts towards OV revalidation qualifications with the event open to all vets, as well as animal health paraprofessionals, nurses and practice managers.
David Babington MRCVS, Business Development Director at Improve International, said: "Moving the OV Conference online has given us an opportunity to harness the technology we use regularly in all of our veterinary training to bring OVs an exceptional but affordable CPD experience.
"Our excellent speakers are looking forward to sharing the latest updates in all aspects of OV work with our delegates and to discussing the challenges ahead, particularly in the light of the COVID-19 pandemic and with the UK moving inexorably towards leaving the EU at the end of the year.
"We’re looking forward to meeting our delegates old and new online at the OV Conference in September.”
The full programme and tickets are now available from https://officialvet.com
The first 150 tickets will get an ‘Early Bird’ 25% discount from £160 to £120+ VAT using the code UK.OV.EARLYBIRD.
All bar one of the suspended drugs contain the NSAID flunixin. The other affected drug is the antibiotic, Tribrissen:
Allevinix 50 mg/ml Solution for Injection for Cattle, Pigs and Horses (Ceva Animal Health)
Cronyxin Injection, 5% w/v Solution for Injection, for cattle and horses (Cross Vetpharm Group Ltd)
Finadyne 50 mg/ml Solution for Injection for cattle, pigs and horses (Intervet UK Ltd)
Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (Norbrook Laboratories Limited)
Meflosyl 5% Solution for Injection for horses and cattle (Zoetis UK Limited)
Norixin 5% Solution for Injection for cattle and horses (Norbrook Laboratories Limited)
Pyroflam 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (Norbrook Laboratories Limited)
Tribrissen 48% Suspension for Injection for horses, pigs and cattle (Intervet UK Ltd)
The British Equine Veterinary Association says that the decision to suspend the drugs was taken without consultation with the veterinary profession, and is urging the VMD to overturn the suspension in horses not destined for the human food chain, to reduce the potential impact on equine welfare.
Jonathan Pycock, BEVA president said: "BEVA is fully supportive of all attempts to promote food safety, however flunixin is widely viewed as the gold-standard pain killer in horses and is commonly used in horses undergoing both elective and emergency surgery, for the crippling pain associated with laminitis and for severe forms of colic.
"BEVA is calling on the VMD to immediately enable limited batch release of flunixin for use in horses not destined for the human food chain in the interests of animal welfare. The equine veterinary profession has always been open to consultation with the VMD on a range of important matters relating to responsible medicine use, antibiotic resistance, horse identification, passports and the horse meat issue. BEVA is perplexed as to why the VMD failed to consult with the equine veterinary industry on the animal welfare impact of withdrawing such an important drug.”
The ten-minute online survey aims to gather a snapshot of horse health over the period of a week.
The results help to identify trends in endemic equine diseases and help the Blue Cross steer equine awareness, education and research.
This year the survey includes some welfare questions to help guide knowledge in response to what the charity calls 'the UK’s horse welfare crisis'.
The National Equine Health Survey is run by the Blue Cross in partnership with the British Equine Veterinary Association. Dodson and Horrell is helping to cover the costs of running the scheme.
Supporters of the survey include the British Horse Society, Horse Trust, Redwings and the Pony Club.
Medal-winning riders Mary and Emily King, and Yazmin Pinchen (pictured right) also support the survey.
Visit www.bluecross.org.uk/NEHS or email NEHS@bluecross.org.uk to register and take part, which carries the chance of winning prizes including Star Lister Clippers, a Lister Adagio Trimmer and some Burford Ariat boots.
Participation in this year’s survey was similar to previous years with 5,235 people taking part and returning records for 15,433 horses. Most horses were kept in livery or a private yard and used for leisure and hacking and the majority within the age range of 5 to 10 years.
A broad variety of breeds were represented, including natives, thoroughbred types and warmbloods.
59% of horses were recorded as healthy and 41% with one or more health problems, compared to 62% and 38% respectively in 2016.
The top five disease syndromes recorded this year were:
Of the 5.5% of horses recorded with back problems 26% were also showing signs of lameness. While the details of the results do not confirm that the two are necessarily connected, these findings reflect the outcome of recent studies conducted by Dr Sue Dyson, Head of Clinical Orthopaedics at the Centre for Equine Studies at the Animal Health Trust.
Sue said: "It is a common observation that horses with lameness stiffen the back as a protective mechanism and develop muscle pain which may be misinterpreted as a primary back problem. We have shown objectively that abolition of lameness by diagnostic analgesia results in an immediate increase in range of motion of the back. The current data supports this close relationship between lameness and back pain."
HRH The Princess Royal has opened the Animal Health Trust's new cancer treatment and research facility in Suffolk.
The facility has been purpose-built to treat horses, dogs and cats with cancer. It will also assist in furthering understanding of the disease in animals.
Peter Webbon, Chief Executive of the AHT, said: "2012 marks 70 years of the AHT fighting disease and injury in animals, and the addition of the Cancer Centre is a landmark achievement in our history. We believe this is the first facility of its kind in Europe, purpose-built to treat horses, dogs and cats with cancer. We now have a short commissioning process to undertake but anticipate welcoming the first patients through the doors in early 2013."
The Kennel Club Cancer Centre at the AHT houses a linear accelerator (pictured right) and brachytherapy machine used in radiotherapy treatment, along with a 16-slice CT scanner to aid radiotherapy planning.
The new facility complements the AHT's existing cancer treatment options of surgery and chemotherapy meaning the Suffolk-based charity will be able to offer each and every patient the very best options for their specific case, whatever the diagnosis. With one in four dogs and one in six cats developing cancer at some time in their life the new centre will help many more animals fight cancer.
Peter Webbon, added: "It was thanks to a generous donation from the late Tom Scott, a long-term supporter of the AHT, that we were able to start this development. His donation, along with that from many other AHT supporters, and an interest-free loan of £1.5 million from the Kennel Club has meant this ambitious project has come to fruition so quickly."
It has taken just over a year to build the Cancer Centre which contains more than 2,600 tonnes of concrete and has eight-feet wide solid concrete walls.
On opening the facility, HRH The Princess Royal, President of the AHT, said: "This Cancer Centre is an exciting development at the AHT and will make a real difference for animals with cancer, here and now. It will improve the chances, for many animals, of beating this pernicious disease.
"Countless other horses, dogs and cats across the world with cancer, who will never be seen by an AHT clinician, will also benefit from knowledge gained from research in The Kennel Club Cancer Centre at the AHT."
The AHT has a strong history in cancer research and the Kennel Club Cancer Centre will enhance the charity's well established cancer research programme. Knowledge gained through the treatment of animals in the facility will contribute to the study of cancers, their causes, early diagnosis and treatment, and ultimately hopefully the prevention of some forms of the disease.
Steve Dean, Kennel Club Chairman, said: "I am very proud to be here today to celebrate the opening of the Kennel Club Cancer Centre. Thanks to the expertise available here at the Animal Health Trust, the Cancer Centre will provide advanced techniques for the diagnosis and treatment of cancer, to the benefit of many animals. It is exciting to consider how synergy between the Kennel Club Cancer Centre and the Kennel Club Genetics Centre can help to further the understanding of the inheritance factors that influence the development of cancer."
A new study1 published in the Equine Veterinary Journal's (EVJ) special American Association of Equine Practitioners supplement has concluded that maggots can play an integral role in modern veterinary care for a variety of wounds in horses.
The study assessed the efficacy of maggot debridement therapy in a diversity of equine lesions and found that the method was beneficial in 93% of cases.
Maggots have been used for the treatment of wounds for hundreds of years. Freshly emerged, germ-free larvae of the common green bottle fly are usually used for the purpose. Their wound-healing action is attributed to a debridement effect, an antiseptic effect, a direct effect on cytokine and cell proliferation involved in wound healing and breakdown of biofilm formation. Maggots also destroy and digest bacteria and may also be beneficial in the fight against multi-drug-resistant bacteria such as MRSA.
The study involved the retrospective analysis of 41 horses with various lesions including foot injury, limb laceration, soft tissue abscesses and musculoskeletal infection. Depending on the type, size and location of the wound the maggots were applied either in direct or indirect contact. In some cases a second maggot application was necessary to reach the desired level of healing. Debridement, disinfection and healing occurred in all but three cases, in less than a week. Of the three that did not respond two were complicated by the presence of tumours and one by pre-existing damage to the underlying bone.
Olivier Lepage of the University of Lyon, who led the study, said: "These results show that maggot debridement therapy potentially has an integral place in modern veterinary wound care. It can be used to treat many types of lesions, although not those involving tumours or bone sequestration. Associated high costs present a limiting factor but maggot debridement therapy should certainly be considered for lesions that fail to respond to conventional methods."
Professor Celia Marr, Editor of the EVJ, said: "Horses often suffer from non-healing wounds, particularly in the limbs where the skin is under continuous movement and there is very little subcutaneous tissue. Although at first glance this study might seem counter-intuitive and we might think of maggots as being the last thing one would want on a clean wound, it shows that maggots can be an effective way to clear damaged tissue and this is an important adjunctive approach in equine wound management."
1The use of maggot debridement therapy in 41 equids OM Lepage, A Doumbia, MF Perron-Lepage and M Gangl. EVJ ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00609.x
The study is published by Wiley-Blackwell and can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.2042-3306.2012.00609.x/abstract
The manufacturer has identified that there is a potential for decreased levels of the preservative Chlorobutanol hemihydrate in the following batch: J2101-03 Expiry 11/2018.
Oxytobel is distributed in the UK by Bimeda UK. Veterinary practices that have purchased this batch number should contact Bimeda to arrange collection.
Any queries in relation to return of the product or credit for the product returned should be addressed to Kay Cowton, Bimeda UK Sales on 01248 725400 or email: uksales@bimeda.com
For further information on the recall please contact Bela-pharm GmbH & Co.KG: +49 (0) 44 41 873 294.
Merial has announced the UK launch of updated ProteqFlu, the first and only EI vaccine in Europe to contain a clade 2 strain.
The company says the new vaccine is also the only one that is fully compliant with the latest 2014 OIE recommended EIV strains.
Louise Radford MRCVS from Merial said: "The launch marks the UK's first and only fully updated equine flu vaccine that contains both a Clade 1 and Clade 2 antigen which includes protection against the latest Florida Clade 2 strain, Richmond 07. This is a significant step for horse health, and the equine industry as a whole."
Hervé Poulet, Merial's head of BioDevelopment and BioResearch said: "Merial has developed strong and unique expertise in the development of non-replicative recombinant canarypox virus-vectored vaccines for various species and diseases.
"For the development of ProteqFlu, our non-replicative recombinant canarypox vector expressing the EI virus haemagglutinin (HA) is used because of its ability to induce a strong cellular immunity which is an essential component in protecting against this highly contagious disease."
Louise added: "ProteqFlu has also demonstrated its success and efficacy in real outbreaks, particularly during the last major outbreak, in Australia in 2007. ProteqFlu was the only vaccine chosen for the eradication programme."
Elanco, a division of Eli Lilly and Company, has launched into the UK companion animal market with a pledge to listen to vets and provide a highly personalised level of support.
The company will initially offer recognised brands such as equine vaccines from the Duvaxyn range, Felocell vaccine for cats and equine wormer Strongid P. It says it is also developing a range of innovative new products designed to address the unmet needs of companion animals, the first of which are expected to be launched during 2011.
Mrs Tina Hunt, a Glasgow Vet School graduate and most recently, Veterinary Business Director at Fort Dodge UK, has been appointed with a remit to build the Elanco Companion Animal Health organisation in the UK. Reporting to Jannes Nijland, Director Elanco Western Europe, she will spearhead the company's growth and relationship building with veterinary practices across the country.
Tina said: "Recent changes in the animal health sector make it an exciting time to be launching a new companion animal brand. The opportunity to be in at the start and to shape a completely new business from scratch was too good to miss. My team shares a passion to combine the best of our experience with new approaches and new ways of working which are more closely attuned to what vets actually want. This means doing things differently and this is a challenge we relish.
We seek a genuine partnership with the profession and look forward to building close, individual relationships with vets and practices, helping them to enable companion animals to live longer, healthier and higher quality lives. While we're a newcomer in this sector, we benefit from the track record and resources available to Elanco, the fifth largest animal company in the world. We're determined to make Elanco Companion Animal Health a trusted and valued partner to vets working in companion animal practice."
Elanco develops and markets products to improve animal health and food-animal production in more than 75 countries. The company employs more than 2,300 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a pharmaceutical corporation. Additional information about Elanco is available at www.elancopet.com and the company can be contacted via email: elancoCAH.uk@lilly.com